Table 3.
In vitro antifungal susceptibilities of clinical isolates of Trichophyton mentagrophytes obtained from human and animal dermatophytosis
| Antifungal agents | Host | MIC (μg/ml) | MIC range | MIC50 | MIC90 | MICGM | Mode | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.004 | 0.008 | 0.016 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ||||||||
| Allylamine | NFT | Humans | 4 | 3 | 10 | 0.008–0.25 | 0.25 | 0.25 | 0.16 | 0.25 | |||||||||||
| Animals | 12 | 8 | 7 | 0.008–0.03 | 0.016 | 0.03 | 0.016ST | 0.008 | |||||||||||||
| TRB | Humans | 6 | 1 (1) | 5 (3) | 5 (5) | 0.004–2 | 1 | 2 | 0.91 | 0.004 | |||||||||||
| Animals | 6 | 8 | 9 | 4 (1) | 0.004–0.03 | 0.016 | 0.03 | 0.02 | 0.016 | ||||||||||||
| Polyenes | AMB | Humans | 3 | 5 | 8 | 1 | 0.06–0.5 | 0.25 | 0.25 | 0.19 | 0.25 | ||||||||||
| Animals | 4 | 9 | 7 | 7 | 0.016–0.125 | 0.06 | 0.125 | 0.06 | 0.03 | ||||||||||||
| GRE | Humans | 1 | 4 | 7 | 5 | 0.25–2 | 1 | 2 | 1.13 | 1 | |||||||||||
| Animals | 2 | 5 | 5 | 7 | 8 (2) | 3 (3) | 0.125–4 | 1 | 2 | 1.44 | 2 | ||||||||||
| Imidazoles | KTC | Humans | 3 | 5 | 4 | 2 (1) | 3 (2) | 0.06–2 | 0.5 | 2 | 0.64 | 0.125 | |||||||||
| Animals | 2 | 3 | 3 | 12 | 7 | 0.06–1 | 0.5 | 1 | 0.53 | 0.5 | |||||||||||
| MCZ | Humans | 3 | 4 | 6 | 4 | 0.016–0.125 | 0.06 | 0.125 | 0.06 | 0.06 | |||||||||||
| Animals | 5 | 5 | 7 | 8 | 2 | 0.008–0.125 | 0.03 | 0.06 | 0.04 | 0.06 | |||||||||||
| ENC | Humans | 9 | 5 | 3 | 0.5–2 | 0.5 | 2 | 0.91 | 0.5 | ||||||||||||
| Animals | 2 | 3 | 4 | 6 | 4 | 8 | 0.03–4 | 0.25 | 4 | 1.56 | 4 | ||||||||||
| Triazoles | ITC | Humans | 1 | 2 | 6 | 3 (1) | 3 (1) | 2 (1) | 0.06–2 | 0.25 | 1 | 0.61 | 0.25 | ||||||||
| Animals | 5 | 5 | 5 | 7 (3) | 2 (2) | 2 (2) | 1 (1) | 0.008–0.5 | 0.03 | 0.125 | 0.07 | 0.06 | |||||||||
| FLC | Humans | 1 | 5 | 4 | 3 | 1 | 2 (1) | 1 (1) | 0.06–32 | 0.25 | 8 | 3.07 | 0.125 | ||||||||
| Animals | 1 | 3 | 4 | 4 | 5 | 1 | 7 | 2 | 0.125–32 | 2 | 16 | 7.44 | 16 | ||||||||
| VRC | Humans | 4 | 6 | 7 | 0.008–0.03 | 0.016 | 0.03 | 0.02 | 0.03 | ||||||||||||
| Animals | 2 | 4 | 7 | 8 | 3 | 3 | 0.008–0.25 | 0.06 | 0.125 | 0.07 | 0.06 | ||||||||||
| Pyridinone derivatives | CPO | Humans | 1 | 2 | 4 | 9 | 1 | 0.004–0.125 | 0.06 | 0.06 | 0.05 | 0.06 | |||||||||
| Animals | 3 | 9 | 8 | 4 | 3 | 0.008–0.125 | 0.03 | 0.06 | 0.04 | 0.016 | |||||||||||
| Phenyl morpholine derivatives | AMR | Humans | 6 | 9 | 1 | 1 | 0.004–0.03 | 0.008ST | 0.008ST | 0.008ST | 0.008 | ||||||||||
| Animals | 7 | 9 | 7 | 2 | 1 | 1 | 0.004–0.125 | 0.008ST | 0.03 | 0.02 | 0.008 | ||||||||||
AMB amphotericin B, AMR amorolfine, CPO ciclopirox, ENC enilconazole, FLC fluconazole, GRE griseofulvin, ITC itraconazole, KTC ketoconazole, MCZ miconazole, NFT naftifine, TRB terbinafine, VRC voriconazole; (n) number of strains derived from patients treated orally with this substance; STstatistically significantly the lowest result in human/animals group